SCHEMBL580291

SCHEMBL580291

CCOC(=O)CCCCC(C)C(=O)OCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
KMT2A Q03164 2/20 0.51
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 3/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ALOX15 P16050 2/20 0.44
HSD17B10 Q99714 1/20 0.44
ATM Q13315 1/20 0.43
DGKA P23743 1/20 0.42
NR1I2 O75469 1/20 0.42
PGR P06401 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
PTGS2 P35354 1/20 0.42
PDE4D Q08499 1/20 0.42
GAA P10253 2/20 0.42
CYP4F2 P78329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL495305 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL493797 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL495782 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL496560 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL494972 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL494426 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL494384 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL495527 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL495112 0.98 KMT2A (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT
SCHEMBL9510213 0.94 CYP1A2 (0.53) CYP1A2KMT2APOLBL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418030-B1 CURING AGENT COMPOSITION KAO CORP (JP) 2019-09-25 EP claimed
US-20120043694-A1 CURING AGENT COMPOSITION KAO CORPORATION (JP) 2012-02-23 US claimed
EP-2418030-A1 CURING AGENT COMPOSITION Kao Corporation (JP) 2012-02-15 EP claimed
EP-2418030-B1 CURING AGENT COMPOSITION KAO CORP (JP) 2019-09-25 EP disclosed
EP-2581148-B1 PROCESS FOR PRODUCTION OF MOLDS KAO CORP (JP) 2018-10-24 EP disclosed
US-8729152-B2 Curing agent composition KAO CORPORATION (JP) 2014-05-20 US disclosed
EP-2287147-B1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-15 EP disclosed
EP-2581148-A1 PROCESS FOR PRODUCTION OF MOLDS Kao Corporation (JP) 2013-04-17 EP disclosed
US-20120261087-A1 PROCESS FOR PRODUCING A MOLD KAO CORPORTATION (JP) 2012-10-18 US disclosed
EP-2123630-B1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-20120043694-A1 CURING AGENT COMPOSITION KAO CORPORATION (JP) 2012-02-23 US disclosed
EP-2418030-A1 CURING AGENT COMPOSITION Kao Corporation (JP) 2012-02-15 EP disclosed
EP-2287147-A2 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed
EP-1637517-B1 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2010-11-10 EP disclosed
EP-2123630-A1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative Taisho Pharmaceutical Co. Ltd. (JP) 2009-11-25 EP disclosed
EP-1637517-A1 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE Taisho Pharmaceutical Co. Ltd. (JP) 2006-03-22 EP disclosed
EP-1370519-A1 SYNTHETIC EXCITATORY AMINO ACIDS ELI LILLY AND COMPANY (US) 2003-12-17 EP disclosed
WO-2002068380-A1 SYNTHETIC EXCITATORY AMINO ACIDS ELI LILLY AND COMPANY (US) 2002-09-06 WO disclosed
CN-1066135-C Ysnthetic excitatory amino acids LILLY CO ELI (US) 2001-05-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120043694-A1 CURING AGENT COMPOSITION ERG28, SMARCA5, MYB CYP1A2 1281/4885KMT2A 465/4885POLB 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.